Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk

Title

Output Type

Speciality

Published

Title

Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults at high surgical risk

Output Type

Advice Statement

Speciality

Cardiovascular System

Published

21 March 2017

Recommendation for NHSScotland

The evidence reviewed offers support for the provision of TAVI for adults with aortic stenosis (AS) who are deemed to be at high surgical risk, although it is worth noting the uncertainty surrounding the generalisability of the trial participants’ risk scores to clinical practice in Scotland. Compared with surgical AVR, TAVI was found to be clinically effective and cost effective.

The evidence review identified a number of ongoing RCTs comparing TAVI with surgical AVR using other devices in a range of patient risk categories that could provide important evidence in the future.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

Is Transcatheter aortic valve implantation (TAVI) clinically and cost effective for severe symptomatic aortic stenosis in adults at high surgical risk?

Why is this important?

TAVI is an alternative to conventional surgical aortic valve replacement (AVR) for operable patients with severe symptomatic aortic stenosis (AS) at high risk for surgical
complications. A Scottish national TAVI service was established in September 2012 in a single centre at the Royal Infirmary of Edinburgh, offering TAVI only to patients deemed not suitable for conventional AVR surgery.

The population prevalence of patients likely to benefit sufficiently from TAVI has yet to be established. 120-140 TAVI procedures are carried out each year in Edinburgh, 75% via transfemoral route, 15% direct aortic route and 10% transapical route. In total, combining individuals with aortic stenosis who are unsuitable for surgery and those at high surgical risk, it is estimated that between 90 to 390 patients per year in Scotland could be eligible for TAVI.

Referred by

National Planning Forum TAVI Review Group

 

Download icon
Download Advice
pdf (205 KB)
Download icon
Download Evidence Note
pdf (1 MB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?